TLPH Talphera, Inc.
Financings ·
Talphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing.
Shares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test.
Talphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary.
Talphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $6.0 million | $6.7 million |
| Net income (loss) | -$14.3 million | -$13.0 million |
| Cash from operations | -$11.4 million | -$12.7 million |
| Cash and equivalents | $5.9 million | $8.9 million |
| Short-term investments | $14.5 million | $0 |
Our latest story on this, dated Jun 5, 2025: "Talphera gets second 180-day Nasdaq bid price period, to December 1, 2025". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 16, 2026: "Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds". The story links the filing or release it is based on. Read the story.
Talphera, Inc. trades under the ticker TLPH on NASDAQ.
Talphera, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:R5XA; LSX:A3DWPN.
The SEC Central Index Key (CIK) for Talphera, Inc. is 1427925. Its filings are on SEC EDGAR.
51,905,796 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Talphera, Inc. under United States.
Our directory classifies Talphera, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Talphera, Inc. is US00444T2096.
aibio.space lists Talphera, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Talphera, Inc. reported a net loss of $14.3 million for the fiscal year ended Dec 31, 2025, and used $11.4 million of cash in operations, per its annual report to the SEC.
$6.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$17.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Talphera, dated Mar 16, 2026: "Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds". Talphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio